M
Michael Schöll
Researcher at University of Gothenburg
Publications - 143
Citations - 9148
Michael Schöll is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Medicine & Dementia. The author has an hindex of 37, co-authored 101 publications receiving 5703 citations. Previous affiliations of Michael Schöll include Karolinska Institutet & University College London.
Papers
More filters
Journal ArticleDOI
PET Imaging of Tau Deposition in the Aging Human Brain
Michael Schöll,Michael Schöll,Samuel N. Lockhart,Daniel R. Schonhaut,James P. O'Neil,Mustafa Janabi,Rik Ossenkoppele,Rik Ossenkoppele,Rik Ossenkoppele,Suzanne L. Baker,Jacob W. Vogel,Jamie Faria,Henry Schwimmer,Gil D. Rabinovici,Gil D. Rabinovici,Gil D. Rabinovici,William J. Jagust,William J. Jagust +17 more
TL;DR: In this paper, the authors defined patterns of tau tracer retention in normal aging in relation to age, cognition, and β-amyloid deposition, and found that older age was associated with increased tracers retention in regions of the medial temporal lobe, which predicted worse episodic memory performance.
Journal ArticleDOI
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Rik Ossenkoppele,Rik Ossenkoppele,Rik Ossenkoppele,Daniel R. Schonhaut,Daniel R. Schonhaut,Michael Schöll,Michael Schöll,Samuel N. Lockhart,Nagehan Ayakta,Nagehan Ayakta,Suzanne L. Baker,James P. O'Neil,Mustafa Janabi,Andreas Lazaris,Averill Cantwell,Jacob W. Vogel,Miguel Santos,Zachary A. Miller,Brianne M. Bettcher,Brianne M. Bettcher,Keith A. Vossel,Joel H. Kramer,Maria Luisa Gorno-Tempini,Bruce L. Miller,William J. Jagust,William J. Jagust,Gil D. Rabinovici,Gil D. Rabinovici +27 more
TL;DR: Results are consistent with and expand upon findings from post-mortem, animal and cerebrospinal fluid studies, and suggest that the pathological aggregation of tau is closely linked to patterns of neurodegeneration and clinical manifestations of Alzheimer's disease.
Journal ArticleDOI
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Thomas K. Karikari,Tharick A. Pascoal,Tharick A. Pascoal,Nicholas J. Ashton,Shorena Janelidze,Andrea Lessa Benedet,Juan Lantero Rodriguez,Mira Chamoun,Melissa Savard,Min Su Kang,Min Su Kang,Joseph Therriault,Michael Schöll,Gassan Massarweh,Jean-Paul Soucy,Kina Höglund,Kina Höglund,Gunnar Brinkmalm,Niklas Mattsson,Sebastian Palmqvist,Serge Gauthier,Erik Stomrud,Henrik Zetterberg,Henrik Zetterberg,Henrik Zetterberg,Oskar Hansson,Pedro Rosa-Neto,Pedro Rosa-Neto,Kaj Blennow,Kaj Blennow +29 more
TL;DR: Blood p-tau181 can predict tau and amyloid β pathologies, differentiate Alzheimer's disease from other neurodegenerative disorders, and identify Alzheimer's Disease across the clinical continuum.
Journal ArticleDOI
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Sebastian Palmqvist,Michael Schöll,Michael Schöll,Olof Strandberg,Niklas Mattsson,Erik Stomrud,Henrik Zetterberg,Henrik Zetterberg,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Susan M. Landau,William J. Jagust,Oskar Hansson +13 more
TL;DR: It is suggested that Aβ fibrils start to accumulate predominantly within certain parts of the DMN in preclinical AD and already then affect brain connectivity before neurodegeneration occurs.
Journal ArticleDOI
Amyloid biomarkers in Alzheimer's disease.
Kaj Blennow,Kaj Blennow,Niklas Mattsson,Niklas Mattsson,Niklas Mattsson,Michael Schöll,Michael Schöll,Oskar Hansson,Henrik Zetterberg,Henrik Zetterberg +9 more
TL;DR: Amyloid biomarkers will be of special value in the clinic to identify patients with brain amyloid deposition at risk for progression to AD dementia, to enable initiation of treatment before neurodegeneration is too severe, and to monitor drug effects on Aβ metabolism or pathology to guide dosage.